Palbociclib (PALBO) is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that has been approved for advanced hormone receptor-positive and HER2-negative breast cancer treatment [46,72,73]. Here, NR4A1 is linked to breast cancer.